Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUDIXIN vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Essential hypertension
Hypertension
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Extensively metabolized in the liver via hydrolysis to reserpic acid and methyl reserpate; also undergoes glucuronidation.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
90-95% bound mainly to albumin and alpha-1 acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
10-30 L/kg; large Vd indicates extensive tissue distribution, including adipose and brain.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 35-50% due to first-pass metabolism; IM: 100%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dose adjustment necessary for mild-to-moderate renal impairment (GFR ≥30 m L/min); severe renal impairment (GFR <30 m L/min): reduce dose by 25–50% and titrate cautiously.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30–50%; Child-Pugh Class C: avoid use or use with extreme caution at reduced doses.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Children 6–12 years: initial dose 0.2 mg/kg/day orally in divided doses, increase gradually up to 0.4–0.6 mg/kg/day; maximum 1.0 mg/kg/day. Not recommended for children <6 years.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Elderly patients: start at 10–50% of adult dose (e.g., 100–200 mg/day orally), titrate slowly due to increased sensitivity and higher risk of sedation, anticholinergic effects, and orthostatic hypotension.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
May cause severe depression, especially in patients with a history of depression.,Use with caution in patients with peptic ulcer disease due to increased gastric acid secretion.,Risk of biliary colic in patients with gallstones.,Avoid use with MAOIs.,May cause withdrawal symptoms (e.g., severe hypertension) upon abrupt discontinuation.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
History of depression (especially suicidal ideation),Active peptic ulcer,Ulcerative colitis,Electroconvulsive therapy (within 7 days),Hypersensitivity to reserpine,Concomitant use with MAOIs
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis. Grapefruit juice may increase reserpine levels. Take with food to reduce gastric irritation.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with neonatal withdrawal syndrome, respiratory depression, hypotonia, and feeding difficulties after prolonged exposure. Avoid use in pregnancy unless no safer alternative exists.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Raudixin (methamphetamine hydrochloride) is contraindicated during breastfeeding due to high secretion into breast milk, potential for infant toxicity (irritability, poor feeding, seizures), and unknown M/P ratio. Discontinue nursing or drug.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Pregnancy reduces methamphetamine clearance by up to 30% due to increased plasma volume and enhanced hepatic metabolism; however, no established dose adjustment in pregnancy. Monitor for toxicity and consider dose reduction if adverse effects occur. Avoid use due to teratogenicity.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
RAUDIXIN (reserpine) is a rauwolfia alkaloid that depletes catecholamines from central and peripheral nerve endings. It causes significant sedation, increased gastric acid secretion (caution in peptic ulcer disease), and nasal congestion. Use is limited due to risk of depression and extrapyramidal symptoms. Monitor for hypotension, especially orthostatic. Avoid concurrent use with MAOIs and tricyclic antidepressants.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Do not stop taking abruptly; withdrawal can cause severe hypertension.,You may feel drowsy or dizzy; avoid driving until you know how the drug affects you.,Report any symptoms of depression, unusual dreams, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold medications containing decongestants.,Rise slowly from sitting or lying to prevent falls due to blood pressure drop.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUDIXIN vs ALDOCLOR-150, answered by our medical review team.
RAUDIXIN is a Antihypertensive that works by Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUDIXIN and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUDIXIN is: Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUDIXIN and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUDIXIN is classified as Category C. First trimester: Known human teratogen; may cause major congenital malformations (e.g., neural tube defects, cardiovascular anomalies). Second and third trimesters: Associated with. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.